Oxford Immunotec Announces First Patients Enrolled in PROTECT Trial for T-SPOT.CMV and T-SPOT.PRT

OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 5, 2015 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced the first patients have been enrolled in the PROTECT Study. The PROTECT study is a pivotal clinical trial designed to demonstrate the clinical value of Oxford Immunotec's T-SPOT®.CMV and T-SPOT.PRT products.

"We are pleased to announce that we have begun the enrollment process for our PROTECT study," said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. "We are excited about the potential application of our T-SPOT.CMV and T-SPOT.PRT products in transplant medicine and the clinical and economic value they could bring to this setting."

About T-SPOT.CMV

Our T-SPOT.CMV test measures the strength of T cell responses to Cytomegalovirus (CMV) as a measure of susceptibility to CMV infection. CMV disease is a common and serious complication in both solid organ and stem cell transplantation. Our T-SPOT.CMV test has the potential to assist clinicians with monitoring anti-viral prophylaxis and evaluating patients at risk from CMV disease. The T-SPOT.CMV test leverages Oxford Immunotec's proprietary T-SPOT technology platform.

About T-SPOT.PRT

Our T-SPOT.PRT (Panel of Reactive T cells) test measures a patient's T cell immune response to foreign tissue to assist in the assessment of risk of graft rejection. Graft rejection is caused by immune responses to the transplanted organ, and both antibody and T cell responses are responsible for rejection events. Our T-SPOT.PRT test is designed to complement commonly used antibody tests, providing additional information on the T cell side of the immune system for which there are currently no good measurement tools. Reducing rejection events is of critical importance to the Transplant community due to the costs and poorer prognosis caused by rejection events. Our T-SPOT.PRT test leverages Oxford Immunotec's proprietary T-SPOT technology platform.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. The Company's initial product is the T-SPOT.TB test, which is used to test for latent tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company has an additional six products in various stages of development that leverage the Company's proprietary technology for measuring cellular (T cell) and innate immune responses. The two most advanced products are focused on the transplantation market. The Company is headquartered near Oxford, UK and in Marlborough, MA. Additional information can be found at www.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.

For Media Inquiries:
Caroline Crawley
Oxford Immunotec
Tel: +44 1235 442796
ccrawley@oxfordimmunotec.com

For Investor Inquiries:
Rick Altieri
Chief Financial Officer
Oxford Immunotec
Tel: +1 (508) 573-9953
raltieri@oxfordimmunotec.com

Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0500
oxfordimmunotec@westwicke.com

Source: Oxford Immunotec